{"id":"W3172653524","doi":"10.1200/jco.2021.39.15_suppl.5044","title":"CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) + rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Enzalutamide; Internal medicine; Prostate cancer; Oncology; PARP inhibitor; Nivolumab; Cohort; Clinical endpoint; Docetaxel; Taxane; Cancer; Clinical trial; Immunotherapy; Poly ADP ribose polymerase; Breast cancer; Androgen receptor","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001180212,0.000782885,0.0008835589,0.0004431453,0.0004451594,0.001197795,0.0006988878,0.0005669554,0.006775971],"category_scores_gemma":[0.001259272,0.0003011852,0.001539792,0.0004476673,0.000311679,0.0004614921,0.0004928354,0.00105319,0.0009768677],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001315766,"about_ca_system_score_gemma":0.001867278,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004103772,"about_ca_topic_score_gemma":0.006709229,"domain_scores_codex":[0.9995591,0.0001458394,0.00002616296,0.0001143372,0.00005326844,0.0001011733],"domain_scores_gemma":[0.9990407,0.0001749996,0.0001950806,0.0001367429,0.0001038307,0.0003486013],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7001189,0.01229071,0.1613556,0.0009996025,0.005765728,0.0008074577,0.0002150558,0.006642463,0.01951751,0.0009886642,0.03417269,0.05712567],"study_design_scores_gemma":[0.1805058,0.1978478,0.5264502,0.0002726574,0.005929846,0.001822621,0.0003283116,0.006451878,0.01274088,0.001136664,0.06638613,0.0001272028],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9467891,0.001190146,0.0007003192,0.0003192562,0.00009872727,0.003711136,0.04240427,0.0001087733,0.004678349],"genre_scores_gemma":[0.9169875,0.0004234802,0.001364966,0.0006966136,0.0001033311,0.002565202,0.07235707,0.00006733224,0.00543448],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006775971,"threshold_uncertainty_score":0.02266788,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1526402380029298,"score_gpt":0.502956627245222,"score_spread":0.3503163892422922,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}